Zeto's wireless EEG machine

News

News

Stratus and Zeto Announce Strategic Distribution Partnership to Expand Access to Point-of-Care EEG in Hospitals Nationwide

Partnership pairs Zeto’s rapid, full-montage EEG headsets with Stratus’ nationwide network of Registered EEG Technologists, giving hospitals a scalable path to high-quality, continuous EEG data in the ICU and ED.

IRVING, TX & RALEIGH, NC – October 15, 2026 – Stratus, a leading provider of neurodiagnostic solutions in the United States, and Zeto, Inc., a next-generation neurotechnology company, today announced a strategic partnership under which Stratus will become an exclusive channel distributor of Zeto’s FDA-cleared point-of-care Zeto ONE™ EEG in hospitals. The collaboration combines Zeto’s novel, rapid-application EEG hardware and AI tools with Stratus’ clinical operations and nationwide network of Registered EEG Technologists (R. EEG T.s), giving hospitals a single, turnkey path to reliable, continuous EEG monitoring in the ICU, ED, and beyond.

“EEG remains one of the most under-resourced diagnostic tools in acute care, constrained less by clinical demand than by a chronic, nationwide shortage of qualified EEG technologists,” said Charlie Alvarez, Chief Executive Officer at Stratus. “Hospitals need EEG devices that are fast and intuitive enough for bedside staff to apply at the point of care, without sacrificing the full-montage signal quality and continuous, technologist-verified oversight that neurologists rely on to catch critical neurological events as they happen. The Stratus-Zeto partnership is designed to close that gap.”      

“Zeto is driven by a simple idea: access to high-quality EEG should not be determined by where a patient happens to be or whether a specialized EEG team is immediately available,” said Florian Strelzyk, PhD, Chief Executive Officer at Zeto. “Our technology is designed to expand EEG access across the continuum of care, from routine testing to the emergency department, ICU, and other settings where timely brain monitoring can change clinical decision-making. Stratus brings tremendous depth in EEG services and technologist expertise. By bringing that depth together with the breadth of Zeto’s platform, we are building a more complete EEG ecosystem and making high-quality brain monitoring available to far more patients.”

The partnership builds on an existing clinical relationship between the two companies. Earlier this year, Zeto and Stratus jointly launched NeuroNotis™, a report that pairs Zeto ONE’s AI-enabled seizure burden detection with technical validation from Stratus Registered EEG Technologists. Zeto brings rapid, guided setup and full-head coverage, including synchronized video and ECG, to the bedside, while Stratus’ remote R. EEG T.s provide the 24/7, eyes-on monitoring and technical review that helps turn raw data into clinically actionable data. This distribution partnership extends that model across Zeto’s hospital product offerings, positioning both companies to scale point-of-care EEG access to health systems nationwide.

Zeto ONE™ is now available in hospitals through Stratus. For more information, visit www.stratusneuro.com or https://zeto-inc.com/

###

About Stratus

Stratus is a leading provider of EEG solutions in the United States and offers global EEG technology via the Stratus EEG software. Stratus offers an array of EEG solutions, from remote ICU and EMU monitoring to world-class EEG review software, ambulatory VEEGs with pruned data, and other custom EEG solutions to fit hospitals’ needs. The company also provides EEG solutions for centralized and decentralized clinical trials, biomarker detection, and access to over 2.2 million hours of anonymized EEG data through its R&D division’s database. To learn more, visit www.stratusneuro.com.

About Zeto

Zeto, Inc., a trailblazer in next-generation neurotechnology, is striving to include an EEG in every relevant health care decision and make brain health insights as common as other vital signs. Powered by its FDA-cleared EEG platform, Zeto enables scalable, real-time measurement of brain activity and provides actionable data to support clinical decision-making, bringing brain monitoring into everyday care environments. The company plans to leverage its platform technology to improve access and quality of medical EEG testing and to facilitate adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018, 2024, and 2026, are commercially available in the United States. To learn more, visit https://zeto-inc.com/.

Zeto Introduces NeuroNotis™: An AI-Enabled Report with Human Review

Combined AI Seizure Detection with Experienced Technical Review to Support More Confident Clinical Decisions

RALEIGH, N.C., April 16, 2026 /PRNewswire/ – Zeto, Inc. today announced the launch of NeuroNotis™, a new offering for hospital customers designed to bring greater confidence to Zeto ONE’s AI-enabled seizure detection. The NeuroNotis Report confirms AI-generated seizure burden scores through review by highly trained, Registered EEG Technologists, with results delivered approximately 15 minutes after the first hour of recording.

Delivered under a service agreement with Stratus, the nation’s largest EEG solutions provider, the NeuroNotis Report combines rapid AI detection with experienced human review to support timely, informed clinical decisions. Stratus, a trusted provider of EEG services for more than 650+ healthcare systems, employs the largest network of R. EEG T.s, including CLTMs and Neuro Analysts. These accomplished Technologists will verify the AI findings during the critical first hour of EEG recording and provide a report to the providers on staff. 

As hospitals increasingly adopt AI tools for seizure detection, many emergency departments and critical care units face uncertainty in making clinical decisions with results provided solely by machine algorithms. The NeuroNotis Report does not replace a physician’s diagnosis but assists by pairing real-time AI analysis with technical review from highly experienced neurodiagnostic professionals to help support a neurologist’s interpretation.

“AI has significantly advanced seizure detection, and we embrace the opportunities it presents. However, a range of challenges remain for many AI approaches currently used,” said Florian Strelzyk, CEO of Zeto. “Some of these challenges are technical, in situations where AI hasn’t quite mastered all clinical edge cases. Others are more related to trust and accountability. The NeuroNotis Report combines the speed of our rapid, full-head coverage Zeto ONE EEG and NeuroPulse* AI-enabled detection with technical review by Stratus’ Registered EEG Technologists. There is no longer a tradeoff between speed and quality – we’re delivering both.”

The NeuroNotis Report is designed to integrate seamlessly into existing workflows, providing:

  • AI-enabled seizure burden analysis in real time
  • Evaluation by a Stratus Registered EEG Technologist
  • Coverage for the critical first hour of EEG recording

All is included in the current costs of Zeto’s service agreements with the hospital, keeping this service cost-neutral.

By combining advanced AI with the expertise of Stratus’ highly qualified EEG Technologists, Zeto continues to expand access to reliable, high-quality EEG data, helping hospitals move from detection to confident action faster than ever before.

In light of the recent release of its New Wave system for outpatient routine and home EEG applications, Zeto continues to expand on its hospital offerings by making NeuroNotis into a core offering for its Zeto ONE™ flagship platform for hospitals and patient transport.

The NeuroNotis Report** is a direct response to demand by physicians, nursing, and clinical care teams to move beyond AI-only interpretations, towards a hybrid, machine-informed but human-driven clinical decision-making process. 

*Powered by encevis

**The NeuroNotis Report is a technical support tool. While Stratus’ Registered EEG Technologists provide a review of AI-flagged events, this review is technical in nature. All clinical interpretations, diagnoses, and patient care decisions are made exclusively by the attending neurologist or qualified physician.

About Zeto, Inc.
Zeto, Inc., a trailblazer in next-generation neurotechnology, is on a mission to make brain health insights as ubiquitous as any other vital sign. Powered by its FDA-cleared EEG platform, Zeto enables scalable, real-time measurement of brain activity and provides actionable data to support clinical decision-making – bringing brain monitoring into everyday care environments.

The company plans to leverage its platform technology to improve access and quality of medical EEG testing and to facilitate adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018, 2024, and 2026, are commercially available in the United States.

To learn more, visit https://zeto-inc.com/ or contact us info@zetoinc.com.

About Stratus
Stratus is the leading provider of EEG solutions in the United States and offers global EEG technology via the StratusEEG software. Stratus offers an array of EEG solutions, from remote ICU and EMU monitoring to world-class EEG review software, ambulatory VEEGs with pruned data, and other custom EEG solutions to fit your needs. The company also provides EEG solutions for centralized and decentralized clinical trials, biomarker detection, and over 9 million hours of recorded EEG data through its R&D division’s database. To learn more, visit stratusneuro.com or contact us at contact@stratusneuro.com

Zeto Announces FDA 510(k) Clearance of Zeto New Wave™, Advancing Efficiency in Outpatient EEG

New product developed to expand access to EEG in outpatient clinics

RALEIGH, N.C., April 2, 2026 /PRNewswire/ – Zeto, Inc., a medical technology company dedicated to making brain health insights through EEG a foundational vital sign in healthcare, announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for Zeto New Wave™, its newest EEG system for outpatient clinics and homes.

Patients across the U.S. often wait weeks for an EEG appointment, delaying critical answers and care. Clinics are also under pressure, facing shortages of specialized EEG technologists and relying on traditional setups that can be slow and cumbersome. Together, these challenges can significantly delay  both patient testing and related follow-up care. 

Zeto New Wave™ is designed to change that. It offers a complete, easy-to-use outpatient routine EEG solution, featuring a full head coverage with 21 soft-tip, no mess electrodes placed according to the widely used 10–20 system. Paired with a compact recording device with built-in display and controls, the system also captures synchronized video and audio, along with optional signals such as ECG, EOG, EMG, orientation sensors, external triggers for event related potentials (ERPs), and integrated photic stimulation detection. 

Designed for short-term recordings of up to 2.5 hours, Zeto New Wave™ enables clinics to perform EEG efficiently and provide timely care to patients.

“New Wave™ is our newest outpatient EEG system, built on lessons learned from our first-generation device, the Zeto WR19,” said Florian Strelzyk, PhD, CEO of Zeto. “We listened to neurologists’ needs and designed a system that helps clinics expand access to EEG, address staffing challenges, and improve patient experience. In 2024, we released the ONE™ specifically for ICUs, EDs and for patient transport, and now with New Wave™ we custom-tailored an ideal solution for physician practices. Both systems run on our Zeto Cloud platform and enable remote access from anywhere. Now, providers can choose which system is best for their needs and budget.”

The FDA clearance of the Zeto New Wave™ marks Zeto’s third FDA-cleared device, alongside Zeto WR19 and Zeto ONE. Zeto offers EEG solutions for critical and emergency care, academic research, clinical trials, and outpatient clinics, and also provides AI-powered seizure detection, seizure burden analysis, and other quantitative analytics. 

Zeto is committed to unlocking the potential of brain health assessment through accessible and actionable neurodiagnostic insights, empowering clinicians to improve routine EEG monitoring, and long-term patient outcomes.

About Zeto, Inc.

Zeto, Inc., a trailblazer in next-generation neurotechnology, is on a mission to make brain health insights as ubiquitous as any other vital sign. Powered by its FDA-cleared EEG platform, Zeto enables scalable, real-time measurement of brain activity and provides actionable data to support clinical decision-making – bringing brain monitoring into everyday care environments.

The company plans to leverage its platform technology to improve access and quality of medical EEG testing and to facilitate adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018, 2024, and 2026 are commercially available in the United States.

To learn more, visit https://zeto-inc.com/ or contact us info@zetoinc.com.

Zeto Announces 2026 Clinical Trial Sponsorship Winners Advancing EEG in Stroke, Delirium, and Epilepsy

Raleigh, NC – March 27, 2026 –  Zeto, Inc., a medical technology company working to make brain health insights through EEG a foundational vital sign in healthcare, announced the recipients of its 2026 Clinical Trial Sponsorship Program, supporting innovative research that brings EEG into real-world clinical environments.

The selected projects demonstrate how EEG can be applied beyond traditional settings to address critical challenges in stroke monitoring, delirium assessment, and epilepsy treatment – where timely, objective brain data can directly impact patient outcomes.

“Research has no borders, and this year’s selected projects reflect a truly global effort to advance EEG – from Australia to the United Kingdom and the United States. Across stroke, delirium, and epilepsy, the common challenge is making EEG practical in real-world care,” said Florian Strelzyk, Ph.D., CEO of Zeto. “These projects show how removing barriers like setup time, patient discomfort, and workflow improvements can unlock new clinical and research applications for EEG.”

The 2026 winners are:

Electrocardiography Brain Perfusion Index (EPBi) – A Promising Biomarker for Continuous Stroke Patient Monitoring, by Prof. Craig Anderson and Dr. Xiaoying Chen (The George Institute for Global Health, Australia)

This study will evaluate EBPi as a biomarker for detecting neurological deterioration in acute ischemic stroke patients. Using Zeto ONE’s full-montage EEG and synchronized ECG capabilities, the project expands monitoring across all cerebral regions, enabling more comprehensive assessment of brain perfusion.

The Delirium Electroencephalography (EEG) and Phenotyping with Endpoints (DEPEND), by Dr. Gregory Scott (Imperial College London, UK)

This study aims to validate portable EEG using Zeto ONE within the DEPEND framework and develop machine learning-based metrics for detecting and grading delirium. By integrating EEG into routine clinical workflows, the project addresses a major unmet need – objective, scalable detection of a condition that remains underdiagnosed and difficult to quantify.

Optimization of Neuromodulation Therapy for Drug-Resistant Epilepsy Using Short-Term Evoked Response Signatures, by Dr. Jonathon J. Parker (Mayo Clinic Arizona, USA)

This project will investigate how short-term EEG biomarkers can guide personalized neuromodulation therapy. By capturing evoked EEG responses with Zeto ONE during routine programming visits, investigators aim to predict treatment response and optimize stimulation parameters for improved seizure control.

Each project will be supported with Zeto EEG systems, gel-free electrodes, access to Zeto’s cloud platform, training, and tools for scalable data collection. Trials are expected to begin later this year.

Now in its third year, Zeto’s Clinical Trial Sponsorship Program continues to gain momentum, attracting an increasing number of high-caliber research proposals. The 2027 competition will open in fall 2026.

About Zeto, Inc.

Zeto, Inc., a trailblazer in next-generation neurotechnology, is on a mission to make brain health insights as ubiquitous as any other vital sign. Powered by its FDA-cleared EEG platform, Zeto enables scalable, real-time measurement of brain activity and provides actionable data to support clinical decision-making – bringing brain monitoring into everyday care environments.

The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are commercially available in the United States.

To learn more, visit https://zeto-inc.com/ or contact research@zetoinc.com.

Zeto Selects Clinical Trial Sponsorship Recipients Advancing EEG in Critical Care, Stroke, and Concussion Research

Santa Clara, CA – July 29, 2025 – Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and cloud platform, is proud to announce the latest recipients of its 2024–2025 Clinical Trial Sponsorship Program.

The program supports the use of EEG in real-world healthcare and clinical research applications by providing teams with access to Zeto’s innovative, rapid-setup, gel-free EEG solution.

“The selected projects reflect the diverse and expanding role of EEG in improving patient outcomes across settings,” said Zoltan Nadasdy, Ph.D., Principal Neuroscientist at Zeto. “From concussion studies in athletes to seizure detection in low-resource ICUs, these projects reflect the power of EEG to transform patient care globally – and the flexibility of Zeto to make it possible.”

The winners are:

Pilot Evaluation of Continuous EEG Implementation for Seizure and Status Epilepticus Management in Zambia (PRECISE-Z) by Clio Rubinos, MD, University of North Carolina

This trial aims to implement continuous EEG (cEEG) monitoring for critically ill patients with altered mental status in Zambia, evaluating its feasibility and acceptability in a resource-limited setting. It also seeks to develop a clinical prediction score to identify patients at highest risk for electrographic seizures and status epilepticus. As one of the first studies exploring cEEG in a lower- to middle-income inpatient setting, it will lay crucial groundwork for improving neurocritical care and reducing disparities in global neurological outcomes.

Optimizing emergency stroke transport strategies using EEG-based biomarkers and machine learning by F. Samuel Racz, MD, University of Texas at Austin

This project aims to improve emergency stroke care by developing a machine learning-based tool that uses EEG recordings to distinguish large vessel occlusion strokes from other conditions with similar early symptoms – before the patient arrives at the hospital. By enabling real-time assessment in the ambulance, this system could help guide whether a patient needs to be transported to the nearest emergency room or instead an endovascular thrombectomy-capable center. If validated, the approach could support future efforts to streamline and optimize stroke triage protocols and reduce treatment delays.

Contribution of Resting and Dynamic Electroencephalogram (EEG) to Assess Athletes Before and After Acute Concussion by Maria Martinez, Ph.D,, University of São Paulo, Brazil

This research will use EEG to evaluate brain activity changes in athletes before and after acute concussion, supporting improved assessment and return-to-play decisions.

Each project will receive Zeto ONE EEG headsets, access to Zeto’s cloud platform, and electrode kits for participants. Trials are expected to begin later this year. 

About Zeto, Inc.

Zeto, Inc., is an award-winning, privately held medical technology company located in Santa Clara, CA, focused on transforming the way electroencephalography is done in clinical and research settings. 

The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit https://zeto-inc.com/ or email us at research@zetoinc.com.

Source: Newswise

Huntsville Memorial Hospital Reduces Patient Transfers and Enhances Local Care with Onsite EEG Program Powered by Zeto

HUNTSVILLE, TX, June 11, 2025 / PRNewswire/ – Zeto, Inc. is proud to announce the success of a new onsite EEG program at Huntsville Memorial Hospital (HMH) that has helped reduce emergency room patient transfers and improve access to neurological diagnostics for the Huntsville community and surrounding areas. As the only hospital within a 30-mile radius, HMH now offers critical services that previously required transfers to larger facilities in Conroe, The Woodlands, or Houston.

An EEG (electroencephalogram) is a test that measures electrical activity in the brain and is commonly used to diagnose seizures, stroke, and other neurological conditions.

Faced with a high volume of neuro-related transfers and limited access to specialty care, HMH leadership assembled a task force to study ER transfer patterns. “We looked at two years of transfer data and saw that many patients were being transferred for neuro-related issues, particularly when an EEG was needed,” said Joe Schorre, Director of Cardiopulmonary and Emergency Management, who led the EEG implementation at HMH. “Our goal was to turn those transfers into local admissions.”

Knowing that the EEG services were needed for Huntsville and Walker County, the hospital explored options for bringing neurological diagnostics in-house as part of a broader inpatient teleneurology and stroke program. The result was the successful implementation of a rapid EEG solution from Zeto that requires no gels or pastes and can be set up by respiratory therapists in under five minutes. “We’re not EEG techs, so we needed a solution that was easy to learn, easy to apply, and could integrate with remote neurologists for interpretation,” said Schorre.

Since the program’s launch in December 2024, HMH has been able to admit more than 40 patients who would otherwise have been transferred to a facility over 30 miles away at a minimum. “Having the ability to implement an EEG program here at HMH is huge step forward for us to elevate the level of care for Walker County residents. Receiving high quality services closer to home which means families and loved ones don’t have to travel, lose time from work, or worry about being separated from loved ones during treatment,” Patrick Shannon, CEO of HMH stated. “For many in our rural community, that makes a huge difference.”

The program has also supported the development of an outpatient EEG program, allowing local primary care providers to refer patients for pre-neurology diagnostic testing. “We’re helping patients get their EEG and MRI here, so by the time they go to the neurologist, they have data in hand,” said Schorre. “It shortens the wait time and gets them the care they need faster.”

Looking ahead, HMH plans to expand services into continuous EEG monitoring and outpatient teleneurology. “This is about doing what’s right for our community. We don’t have local neurology, but we do have smart, committed staff and the tools to support them,” said Schorre.

About Huntsville Memorial Hospital
Huntsville Memorial Hospital, Huntsville, Texas, is currently a 123-bed, CIHQ‐accredited, not‐for‐profit acute care community hospital. HMH delivers quality healthcare services to the residents of Walker County and its surrounding communities, a population of more than 82,000. HMH and its dedicated staff offer compassionate care and the latest technologies and treatment solutions. HMH holds the American Heart Association Primary Stroke Center designation. HMH keeps community health and wellness at the forefront of its mission. Please visit us at www.huntsvillememorial.com.

Source: PRNewswire

Zeto, Inc. joins Innovators’ Network at American Heart Association Center for Health Technology & Innovation

American Heart Association consortium advances development of evidence-based health tech solutions

SANTA CLARA, Calif., May 29, 2025 /PRNewswire/ – Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and advanced cloud platform, has joined the American Heart Association Center for Health Technology & Innovation’s (the Center) Innovators’ Network. The Center is focused on building and fostering health technology relationships to develop innovative and scalable solutions. 

The Innovators’ Network is a consortium connecting entrepreneurs, providers, researchers and payers to advance cardiovascular and brain health innovation. Innovators’ Network members also have the opportunity to access the Association’s digital evidence-based scientific guidelines and clinical recommendations as they develop digital healthcare technologies. Members interact with the Center in different ways, including building models for clinical outcome studies, which lowers the significant cost of developing those studies independently, helping connect the science to technology and providing evidence that a digital platform improves healthcare outcomes – a key concern for providers and payers.

“The Center aims to advance the rapid, efficient and effective development of healthcare technology,” said Robert A. Harrington, M.D., FAHA, said Robert A. Harrington, M.D., FAHA, volunteer past president of the American Heart Association (2019-2020), chair of the American Heart Association’s Health Tech Advisory Group for the Center and the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine and provost for medical affairs of Cornell University. “Joining the Innovators’ Network gives members the opportunity to leverage the consortium and work toward broadening and deepening their engagement in this arena.”

“We’re happy to join the American Heart Association’s Innovators’ Network to advance scalable, evidence-based solutions in neurology,” said Aswin Gunasekar, Founder and CEO of Zeto, Inc. “At Zeto, we strive to bridge clinical needs with technology that’s both accessible and impactful. We’re excited to join the Center to drive meaningful innovation in brain monitoring and improve outcomes in critical care and beyond.”

Non-convulsive status epilepticus (prolonged seizures) is a major neuro-emergency in acute care, with up to 1 in 3 neurological ICU patients at risk for seizures that can lead to brain injury or death. To help address this challenge, Zeto offers rapid, full-montage EEG with AI-powered status epilepticus and seizure detection — enabling timely, bedside diagnosis and intervention when it matters most.
1 Seizure Management in the Intensive Care Unit – PMC

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-powered notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like stroke and traumatic brain injury. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source: Newswise

Zeto Unveils NeuroPulse, the First AI-Powered Status Epilepticus Software Using Full 10-20 EEG in Collaboration with encevis*

SANTA CLARA, Calif., April 2, 2025 /PRNewswire/ — Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and advanced cloud platform, announces the integration of live bedside AI-powered Seizure Burden and Status Epilepticus detection. Utilizing encevis, a leading FDA-cleared EEG analysis software developed by the Austrian Institute of Technology, this new capability enhances EEG monitoring with automated detection and notifications for Status Epilepticus—a life-threatening, prolonged seizure condition requiring immediate intervention.

Up to one-third of neurological critical care and emergency department patients are at risk for seizures, which can lead to permanent brain injury and increased mortality risk1. Access to timely EEG interpretation remains an unmet need, particularly in emergency and critical care settings, where rapid and reliable medical intervention is essential.2

“Our product development has been guided by neurologists, critical and emergency care physicians who sought rapid, clinical-grade EEG with full-head coverage and video to not miss clinically relevant events3. They emphasized the need for accurate bedside seizure detection that enables real-time review and validation by neurologists, ensuring patients receive timely and appropriate treatment,” said Aswin Gunasekar, Founder and CEO of Zeto, Inc. “We introduced the Zeto ONE, a best-in-class, full 10-20 EEG system offering rapid setup, video, and remote reading services—being fast embraced by U.S. hospitals. With the addition of AI-powered seizure detection, we now offer a comprehensive, all-in-one solution that significantly enhances neurocritical assessment.”

encevis utilizes a cutting-edge AI model to detect seizures, seizure burden, and electrographic status epilepticus. Trained on a diverse dataset of over 21,400 hours of EEG recordings from more than 800 patients, the model was further validated using an independent dataset from 81 patients. Expert reviewers from top U.S. and European institutions meticulously labeled the data, ensuring highly accurate and clinically meaningful insights.

“We are delighted to continue our successful partnership with Zeto,” said Dr. Tilmann Kluge, Head of Medical Signal Analysis at AIT Austrian Institute of Technology. “Our algorithms allow physicians to detect seizure burden and electrographic status epilepticus early and with high sensitivity without the need for continuous expert monitoring of the EEG. Our EEG analysis software has been utilized by leading hospitals for over a decade, with capabilities such as artifact reduction, spike and seizure detection with high sensitivity and specificity.”

Zeto’s full 10-20 EEG platform now features AI-powered seizure burden detection with advanced EEG analysis tools providing comprehensive clinical value for ICU Monitoring as required by ACNS, the American Clinical Neurophysiology Society. Supported by nationwide neurologist reading services, hospitals can expand EEG access without additional infrastructure. More healthcare providers are adopting rapid EEG-powered diagnostics, enabling timely, life-saving decisions.

To learn more about how Zeto’s solutions can be integrated into your hospital, contact us at sales@zetoinc.com.

* The encevis Component for Detection of Seizures and Electrographic Status Epilepticus is indicated for the detection of Seizures and Electrographic Status Epilepticus in patients greater than or equal to 18 years of age who are at risk for seizures.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like depression, stroke and traumatic brain injury. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

About Medical Signal Analysis at AIT (Austrian Institute of Technology)

Medical Signal Analysis at AIT is dedicated to the development of powerful algorithm and medical software solutions for the analysis of neurophysiological data. As part of the Austrian Institute of Technology, Austria’s largest non-university research institute, the team of researchers and software professionals developed the CE certified and FDA cleared EEG analysis software suite ‘encevis‘ which is included in EEG platforms in Europe and the US The algorithms and software for Zeto, Inc., are the most recent developments.

1 Kozak, R., et al. (2023). JACEP Open. 4(4)
2 Herman, S.T., et al. (2015) J Clin Neurophysiol. 32(2):87-95
3 Rubin MN, et al. Neurohospitalist (2014) PMID: 24381704; PMCID: PMC3869310

Source – PRNewswire

Zeto, Inc., Secures $31 Million In Series B Funding To Redefine The Future Of EEG Brain Monitoring

SANTA CLARA, Calif., Jan. 8, 2025 /PRNewswire/ — Zeto, Inc., a fast-growing medical technology company revolutionizing EEG diagnostics with its cutting-edge devices and AI-driven cloud platform, has announced the recent successful closing of a $31 million funding round.

The funding round was led by MindWorks Global (MWG), a Michigan-based investment entity funded by visionary entrepreneur-investors with a track record of building multi-billion-dollar enterprises. MWG’s Founder, CEO and Lead Partner, Mike Williams, is an accomplished entrepreneur and investor known for his expertise in scaling companies across different industries, including achieving a $1.1 billion exit from his most recent venture. Mike Williams said, “Zeto’s vision and technology are truly transformative for the medical arena and beyond, and we are excited to leverage our expertise and network to help drive the company’s growth. The world of EEG is going to be transformed immensely in the upcoming years, and Zeto is going to be at the forefront of it. Brain health assessment will extend beyond traditional healthcare, and we’re excited to support Zeto in pioneering new frontiers. It’s an exciting day!”

Aswin Gunasekar, Zeto’s Founder and CEO said, “Zeto has reached a pivotal milestone, earning a reputation for game-changing innovation and experiencing rapid adoption of our solutions by leading healthcare institutions across the U.S. Our management team has long aspired to collaborate with accomplished entrepreneur-investors who have successfully scaled companies to drive meaningful societal impact and significant revenue. We are excited to welcome MindWorks Global partners to our board of directors who bring not only capital but also invaluable expertise, extensive experience, and a powerful network. Our dedicated team is eager to embark on this exciting next chapter in our company’s journey.”

Zeto is grateful for the steadfast support and continued investments from its prior investors over the years. This new funding will enable Zeto to expand its commercial and operational teams, drive further growth and strengthen ongoing research and development efforts.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology company, is at the forefront of advancing EEG brain monitoring and diagnostics in healthcare. Through its innovative wearable devices, Zeto makes brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home. Backed by a powerful cloud-based platform, Zeto delivers nationwide monitoring and interpretation services by neurologists, along with AI-driven notifications for conditions such as seizures and epilepsy. Looking ahead, Zeto plans to expand its capabilities to detect and manage conditions like depression, stroke and traumatic brain injury. Zeto’s EEG systems, which received FDA clearances in 2018 and 2024, are currently commercially available in the United States.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – PRNewswire

Zeto Among America’s Fastest-Growing Private Companies on the 2024 Inc. 5000 List

NEW YORK, August 13, 2024 – Inc. revealed today that Zeto, Inc. ranks No. 1311 on the 2024 Inc. 5000, its annual list of the fastest-growing private companies in America. The prestigious ranking provides a data-driven look at the most successful companies within the economy’s most dynamic segment—its independent, entrepreneurial businesses. Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, Patagonia, and many other household-name brands gained their first national exposure as honorees on the Inc. 5000.

“We are truly honored to be recognized on the Inc. 5000 list of America’s fastest-growing companies. This achievement reflects the dedication and hard work of the entire Zeto team. With the recent FDA 510(k) clearance of our groundbreaking next-generation EEG brain monitoring product, Zeto ONE, we are confident that our growth will continue as we advance EEG monitoring in critical care, outpatient, and home settings. The market potential for our solutions is enormous, offering significant opportunities for continued growth and impact,” stated Aswin Gunasekar, Founder and CEO of Zeto.

The Inc. 5000 class of 2024 represents companies that have driven rapid revenue growth while navigating inflationary pressure, the rising costs of capital, and seemingly intractable hiring challenges. Among this year’s top 500 companies, the average median three-year revenue growth rate is 1,637 percent. In all, this year’s Inc. 5000 companies have added 874,458 jobs to the economy over the past three years.

For complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, location, and other criteria, go to www.inc.com/inc5000. All 5000 companies are featured on Inc.com starting Tuesday, August 13, and the top 500 appear in the new issue of Inc. magazine, available on newsstands beginning Tuesday, August 20.

“One of the greatest joys of my job is going through the Inc. 5000 list,” says Mike Hofman, who recently joined Inc. as editor-in-chief. “To see all of the intriguing and surprising ways that companies are transforming sectors, from health care and AI to apparel and pet food, is fascinating for me as a journalist and storyteller. Congratulations to this year’s honorees, as well, for growing their businesses fast despite the economic disruption we all faced over the past three years, from supply chain woes to inflation to changes in the workforce.”

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare. Offering wearable devices, Zeto makes brain monitoring accessible across various clinical settings including the ICU, ED, hospital, office, and home. Supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled notifications for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury. 

More about Inc. and the Inc. 5000

Methodology

Companies on the 2024 Inc. 5000 are ranked according to percentage revenue growth from 2020 to 2023. To qualify, companies must have been founded and generating revenue by March 31, 2020. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2023. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2020 is $100,000; the minimum for 2023 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. Growth rates used to determine company rankings were calculated to four decimal places.

About Inc.

Inc. Business Media is the leading multimedia brand for entrepreneurs. Through its journalism, Inc. aims to inform, educate, and elevate the profile of our community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating our future. Inc.’s award-winning work achieves a monthly brand footprint of more than 40 million across a variety of channels, including events, print, digital, video, podcasts, newsletters, and social media. Its proprietary Inc. 5000 list, produced every year since its launch as the Inc. 100 in 1982, analyzes company data to rank the fastest-growing privately held businesses in the United States. The recognition that comes with inclusion on this and other prestigious Inc. lists, such as Female Founders and Power Partners, gives the founders of top businesses the opportunity to engage with an exclusive community of their peers, and credibility that helps them drive sales and recruit talent. For more information, visit www.inc.com.

Source – PRNewswire